International Assets Investment Management LLC Invests $10.35 Million in DaVita Inc. (NYSE:DVA)

International Assets Investment Management LLC acquired a new stake in shares of DaVita Inc. (NYSE:DVA - Free Report) in the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor acquired 63,113 shares of the company's stock, valued at approximately $10,346,000. International Assets Investment Management LLC owned about 0.07% of DaVita as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds have also made changes to their positions in DVA. Harvard Management Co. Inc. acquired a new position in DaVita in the 2nd quarter valued at approximately $55,115,000. Lazard Asset Management LLC raised its stake in shares of DaVita by 147.3% in the first quarter. Lazard Asset Management LLC now owns 256,872 shares of the company's stock valued at $35,460,000 after purchasing an additional 153,008 shares in the last quarter. Jupiter Asset Management Ltd. lifted its position in DaVita by 146.7% in the first quarter. Jupiter Asset Management Ltd. now owns 187,177 shares of the company's stock worth $25,840,000 after purchasing an additional 111,311 shares during the period. Point72 Asset Management L.P. acquired a new stake in DaVita during the second quarter worth $9,615,000. Finally, Hennessy Advisors Inc. bought a new stake in DaVita in the 2nd quarter valued at $8,439,000. Institutional investors own 90.12% of the company's stock.

Insider Buying and Selling

In other DaVita news, insider Kathleen Alyce Waters sold 7,857 shares of the stock in a transaction on Tuesday, August 13th. The stock was sold at an average price of $146.21, for a total value of $1,148,771.97. Following the transaction, the insider now directly owns 83,011 shares in the company, valued at approximately $12,137,038.31. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In related news, CEO Javier Rodriguez sold 32,176 shares of the stock in a transaction that occurred on Monday, August 26th. The shares were sold at an average price of $155.93, for a total value of $5,017,203.68. Following the transaction, the chief executive officer now directly owns 905,659 shares in the company, valued at $141,219,407.87. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, insider Kathleen Alyce Waters sold 7,857 shares of the firm's stock in a transaction that occurred on Tuesday, August 13th. The shares were sold at an average price of $146.21, for a total transaction of $1,148,771.97. Following the completion of the transaction, the insider now directly owns 83,011 shares in the company, valued at approximately $12,137,038.31. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 173,482 shares of company stock worth $27,387,069 in the last quarter. Insiders own 2.00% of the company's stock.

DaVita Price Performance

Shares of DVA stock traded down $1.41 during trading hours on Thursday, hitting $139.81. 1,174,019 shares of the company's stock were exchanged, compared to its average volume of 818,897. DaVita Inc. has a 52 week low of $76.17 and a 52 week high of $168.50. The stock has a market cap of $11.73 billion, a price-to-earnings ratio of 14.89, a price-to-earnings-growth ratio of 0.90 and a beta of 0.87. The company has a debt-to-equity ratio of 9.94, a current ratio of 1.16 and a quick ratio of 1.12. The stock's 50-day moving average is $157.96 and its 200-day moving average is $145.97.

DaVita (NYSE:DVA - Get Free Report) last posted its quarterly earnings data on Tuesday, October 29th. The company reported $2.59 earnings per share for the quarter, missing the consensus estimate of $2.76 by ($0.17). DaVita had a net margin of 6.86% and a return on equity of 77.00%. The company had revenue of $3.26 billion during the quarter, compared to analyst estimates of $3.25 billion. During the same quarter in the previous year, the business posted $2.85 EPS. The company's revenue was up 4.6% compared to the same quarter last year. As a group, research analysts forecast that DaVita Inc. will post 9.99 EPS for the current year.

Wall Street Analyst Weigh In

Several analysts have recently weighed in on DVA shares. Bank of America lifted their target price on shares of DaVita from $139.00 to $145.00 and gave the company an "underperform" rating in a research report on Wednesday, August 7th. UBS Group upped their price objective on DaVita from $169.00 to $175.00 and gave the company a "buy" rating in a research note on Thursday, August 8th. Truist Financial raised their target price on DaVita from $165.00 to $175.00 and gave the stock a "hold" rating in a research report on Monday, October 7th. TD Cowen upped their price target on DaVita from $139.00 to $150.00 and gave the company a "hold" rating in a research report on Wednesday, July 24th. Finally, Barclays lifted their price objective on DaVita from $150.00 to $164.00 and gave the company an "equal weight" rating in a report on Thursday. One investment analyst has rated the stock with a sell rating, three have given a hold rating and two have issued a buy rating to the company. Based on data from MarketBeat, the company has an average rating of "Hold" and an average price target of $161.80.

DaVita Company Profile

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.